STOCK TITAN
  1. Home
  2. Sec-filings
  3. VERV
  4. [SC 14D9/A] Verve Therapeutics, Inc. Amended Tender Offer Recommendation

[SC 14D9/A] Verve Therapeutics, Inc. Amended Tender Offer Recommendation

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SC 14D9/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock VERV logo
Verve Therapeutics, Inc.

NASDAQ:VERV

VERV Rankings

#2725 Ranked by Market Cap
N/A Ranked by Dividends

VERV Latest News

Jul 25, 2025
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jul 24, 2025
Lilly and Verve announce expiration of Verve tender offer
Jun 17, 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jun 2, 2025
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 28, 2025
Verve Therapeutics to Participate in Upcoming Investor Conferences

VERV Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G] Verve Therapeutics, Inc. SEC Filing
Aug 14, 2025
[SCHEDULE 13G/A] Verve Therapeutics, Inc. SEC Filing
Aug 4, 2025
[15-12G] Verve Therapeutics, Inc. SEC Filing
Jul 28, 2025
[SCHEDULE 13G/A] Verve Therapeutics, Inc. SEC Filing
Jul 28, 2025
[Form 4] Verve Therapeutics, Inc. Insider Trading Activity

VERV Stock Data

994.04M
84.54M
5.1%
94.69%
4.06%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON